Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1719284

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the adequacy of access to (a) Creon and (b) other drugs that contain pancreatic enzymes for patients after pancreatic surgery.
tabling member constituency	Broxbourne
tabling member printed	Sir Charles Walker
uin	26982
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10,000 gastro-resistant capsules; Creon 25,000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 15:24:29 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1493 label Biography information for Sir Charles Walker

711792

registered interest
date	16/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects a decision to be made on approval of the Onivyd drug for NHS use in the treatment of pancreatic cancer.
tabling member constituency	Upper Bann
tabling member printed	David Simpson
uin	68230
answer	answer is ministerial correction date of answer 24/03/2017 answer text <p>The National Institute for Health and Care Excellence currently expects to publish final guidance on the use of Onivyde (pegylated liposomal irinotecan) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy in April 2017.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 24/03/2017 14:39:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1597 label Biography information for David Simpson

417657

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the level of provision of pancreatic cancer treatment on the NHS; and if he will make a statement.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9405
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>Over the last 15 years, services for pancreatic cancer have been significantly strengthened within the National Health Service. This includes clearer diagnostic pathways, decision making by specialist multi-disciplinary teams and centralisation of pancreas surgery within specialist teams.</p><p> </p><p> </p><p> </p><p>Between 1999 and 2009, following reorganisation of pancreas services, there are now twice as many patients accessing surgery, and one year survival has increased by 5%. The benefits of the United Kingdom model are recognised internationally.</p><p> </p><p> </p><p> </p><p>It is recognised that pancreatic cancer is a challenging disease for a number of reasons. There is a lack of any effective drug therapies and research opportunities are restricted by the small number of patients with the disease (approximately 7,000 annually), and the relatively low survival rates.</p><p> </p><p> </p><p> </p><p>Symptoms are variable and difficult to identify, and there is presently no diagnostic test, although a test is in the research phase.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/09/2015 12:25:49 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

417658

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that expert clinicians are consulted when assessing new treatments for pancreatic cancer.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9406
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The National Institute for Health and Care Excellence’s (NICE) guidance is based on a thorough assessment of the available evidence and is developed through wide consultation with stakeholders. NICE makes every effort to ensure that appropriate stakeholders, including clinical experts, are able to engage with the development of its guidance.</p><p> </p><p> </p><p> </p><p>As part of NICE’s technology appraisal process, clinical specialists, commissioning experts and patient experts are invited by the Appraisal Committee to provide written evidence and attend the Committee meeting to help in the Committee's discussion of the technology being appraised.</p><p> </p><p> </p><p> </p><p>NHS England is responsible for administering the Cancer Drugs Fund (CDF) and decisions on which treatments are included on the national CDF list are made by the CDF clinical panel. The panel includes expert oncologists, oncology pharmacists and patient representatives.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:55:39 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

417664

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the reasons are for the most recent NHS England review of the pancreatic cancer drug available on the national Cancer Drugs Fund.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9391
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The Cancer Drugs Fund panel considered a number of drug/indications for reprioritisation in July 2015. The panel’s decisions were announced on 4 September 2015 and are available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/cdf-drug-sum/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/cdf-drug-sum/</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:57:19 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

348134

registered interest
date	02/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that the treatments for pancreatic cancer listed by the Cancer Drugs Fund will continue to be made available to patients on the NHS.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	917
answer	answer is ministerial correction date of answer 10/06/2015 answer text <p>The Cancer Drugs Fund has already helped over 72,000 people in England and this year £340 million will be provided so people get the drugs they need.</p><p> </p><p> </p><p> </p><p>The operation of the Cancer Drugs Fund (CDF), including which drugs remain in the Fund, is a matter for NHS England. The national CDF list is reviewed regularly and includes several treatments for pancreatic cancers such as:</p><p> </p><p> </p><p> </p><p>Albumin Bound Paclitaxel (Abraxane) for the first line treatment of advanced adenocarcinoma of the pancreas in combination with gemcitabine; Peptide Receptor Radionucleotide Therapy for the treatment of advanced pancreatic neuroendocrine tumours; and Sunitinib (Sutent) for the treatment of pancreatic neuroendocrine carcinomas.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/06/2015 16:23:13 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

173200

registered interest
date	12/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much of the Cancer Drugs Fund was spent on pancreatic cancer drugs in each year since 2010.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	220490
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>NHS England has advised that there is currently one anti-cancer therapy available through the Cancer Drugs Fund that is used in pancreatic cancers. This is Abraxane (albumin bound paclitaxel).</p><p> </p><p> </p><p> </p><p>NHS England has estimated that, since Abraxane was added to the national Cancer Drugs Fund list in March 2014, the estimated spend in that financial year was approximately £13,000.</p><p> </p><p> </p><p> </p><p>Based on current application rates for this drug, NHS England estimates that approximately £4.09 million will be spent on this drug in 2014-15.</p><p> </p><p> </p><p> </p><p>Prior to April 2013, information on the indication for which a cancer drug was provided through the Fund was not collected.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/01/2015 13:35:17 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

169543

registered interest
date	10/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that NHS England acknowledges unmet need when re-evaluating treatments for pancreatic cancer on the Cancer Drugs Fund list.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	218192
answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>The decision-making process adopted by the Cancer Drugs Fund panel is set out in the Standard Operating Procedures of the Fund, which are available on NHS England’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p><p> </p><p> </p><p>This document sets out the factors the panel will take into account, including unmet need.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/12/2014 17:04:28 answering member 4020 label Biography information for George Freeman
tabling member	4037 label Biography information for Tom Blenkinsop

167781

registered interest
date	03/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress he has made on the decision-making process on whether the most effective medicines will continue to be made available to patients with pancreatic cancer on the NHS.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	217091
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the National Health Service on the clinical and cost-effectiveness of health technologies. NICE has been asked to appraise a number of pancreatic cancer drugs and commissioners will continue to be legally required to fund treatments recommended by NICE technology appraisal guidance. <br> <br></p><p> </p><p>Decisions on the drugs made available through the Cancer Drugs Fund are a matter for NHS England’s Cancer Drugs Fund panel. The standard operating procedures for the Fund, which outline the decision-making process the panel follows is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p><p> </p><p> </p><p>We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 15:06:06 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

167782

registered interest
date	03/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NHS England on recognising incremental innovation in pancreatic cancer treatment when assessing medicines for inclusion on the Cancer Drugs Fund.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	217092
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>Decisions on the drugs made available through the Cancer Drugs Fund are a matter for NHS England’s Cancer Drugs Fund panel. We have had no discussions. The standard operating procedures for the Fund, which outline the decision-making process the panel follows is available at:</p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p><p> </p><p> </p><p>Such decisions are made by an expert panel of clinicians which also includes patient representation. Additionally the panel will use its expert judgement in making final decisions and will be aware of specific issues relating to current treatment options for a given disease area.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 15:03:21 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper